WO2012095432A3 - Agents de liaison à tlr3 - Google Patents

Agents de liaison à tlr3 Download PDF

Info

Publication number
WO2012095432A3
WO2012095432A3 PCT/EP2012/050321 EP2012050321W WO2012095432A3 WO 2012095432 A3 WO2012095432 A3 WO 2012095432A3 EP 2012050321 W EP2012050321 W EP 2012050321W WO 2012095432 A3 WO2012095432 A3 WO 2012095432A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding agents
tlr3 binding
tlr3
antibodies
autoimmune
Prior art date
Application number
PCT/EP2012/050321
Other languages
English (en)
Other versions
WO2012095432A2 (fr
Inventor
Laurent Gauthier
Catherine Massacrier
Yannis Morel
Carine Paturel
Cécile BONNAFOUS
Mette Dahl Andersen
Benjamin Rossi
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Priority to EP12700056.0A priority Critical patent/EP2663329A2/fr
Priority to CA2824313A priority patent/CA2824313A1/fr
Priority to US13/979,370 priority patent/US20140065154A1/en
Priority to AU2012206614A priority patent/AU2012206614A1/en
Publication of WO2012095432A2 publication Critical patent/WO2012095432A2/fr
Publication of WO2012095432A3 publication Critical patent/WO2012095432A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des anticorps anti-TLR3, ainsi que leurs procédés de fabrication et d'utilisation. Les anticorps sont particulièrement adaptés au traitement de maladies auto-immunes ou inflammatoires à l'aide d'anticorps anti-TLR3.
PCT/EP2012/050321 2011-01-12 2012-01-10 Agents de liaison à tlr3 WO2012095432A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP12700056.0A EP2663329A2 (fr) 2011-01-12 2012-01-10 Agents de liaison à tlr3
CA2824313A CA2824313A1 (fr) 2011-01-12 2012-01-10 Agents de liaison a tlr3
US13/979,370 US20140065154A1 (en) 2011-01-12 2012-01-10 Tlr3 binding agents
AU2012206614A AU2012206614A1 (en) 2011-01-12 2012-01-10 TLR3 binding agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431967P 2011-01-12 2011-01-12
US61/431,967 2011-01-12

Publications (2)

Publication Number Publication Date
WO2012095432A2 WO2012095432A2 (fr) 2012-07-19
WO2012095432A3 true WO2012095432A3 (fr) 2012-09-13

Family

ID=45446068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/050321 WO2012095432A2 (fr) 2011-01-12 2012-01-10 Agents de liaison à tlr3

Country Status (5)

Country Link
US (1) US20140065154A1 (fr)
EP (1) EP2663329A2 (fr)
AU (1) AU2012206614A1 (fr)
CA (1) CA2824313A1 (fr)
WO (1) WO2012095432A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130090457A1 (en) * 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
AU2010270163B2 (en) 2009-07-10 2016-05-05 Innate Pharma, S.A. TLR3 binding agents
US9944712B2 (en) 2012-05-31 2018-04-17 Innate Pharma TLR3 binding agents
EP2996715A1 (fr) * 2013-05-14 2016-03-23 Innate Pharma Méthodes pour restaurer la sensibilité aux corticostéroïdes
EP4249913A1 (fr) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Inhibiteur du récepteur de type toll 3 pour la prévention et/ou le traitement de troubles chez des patients ayant des antécédents personnels de thromboembolie veineuse (vte)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127113A2 (fr) * 2009-04-29 2010-11-04 Centocor Ortho Biotech Inc. Antagonistes du récepteur 3 de type toll
WO2011004028A2 (fr) * 2009-07-10 2011-01-13 Innate Pharma Agents de liaison à tlr3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
ES2279572T3 (es) 1997-05-07 2007-08-16 Schering Corporation Proteinas receptoras humanas de tipo toll, reactivos y metodos relacionados.
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
CA2433353C (fr) 2000-12-28 2017-03-21 Altus Biologics, Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
JP2004016021A (ja) 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
EP1945820B1 (fr) 2005-10-27 2013-08-28 Janssen Biotech, Inc. Modulateurs du récepteur de type toll 3, et leurs procédés et utilisations
WO2008049897A1 (fr) 2006-10-27 2008-05-02 Ablynx N.V. Administration intranasale de polypeptides et de protéines
EP2281043B1 (fr) 2008-04-25 2013-03-13 Innate Pharma Compositions agonistes de tlr3 améliorées
LT2350304T (lt) 2008-10-31 2017-02-10 Janssen Biotech, Inc. Toll tipo receptoriaus 3 antagonistai

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127113A2 (fr) * 2009-04-29 2010-11-04 Centocor Ortho Biotech Inc. Antagonistes du récepteur 3 de type toll
WO2011004028A2 (fr) * 2009-07-10 2011-01-13 Innate Pharma Agents de liaison à tlr3

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOTOS I ET AL: "The Toll-like receptor 3:dsRNA signaling complex", BBA - GENE REGULATORY MECHANISMS,, vol. 1789, no. 9-10, 1 September 2009 (2009-09-01), pages 667 - 674, XP026737895, ISSN: 1874-9399, [retrieved on 20090709], DOI: 10.1016/J.BBAGRM.2009.06.005 *
DUFFY ET AL: "Down modulation of human TLR3 function by a monoclonal antibody", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 248, no. 2, 26 December 2007 (2007-12-26), pages 103 - 114, XP022401829, ISSN: 0008-8749, DOI: 10.1016/J.CELLIMM.2007.10.002 *
K. A. CAVASSANI ET AL: "TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 205, no. 11, 1 January 2008 (2008-01-01), pages 2609 - 2621, XP055008983, ISSN: 0022-1007, DOI: 10.1084/jem.20081370 *
MENG LIESU ET AL: "Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 3, 25 May 2010 (2010-05-25), pages R103, XP021085231, ISSN: 1478-6354, DOI: 10.1186/AR3034 *
RANJITH-KUMAR C T ET AL: "Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain", JOURNAL OF BIOLOGICAL CHEMISTRY 20070302 AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY INC. US,, vol. 282, no. 10, 2 March 2007 (2007-03-02), pages 7668 - 7678, XP007914953 *
TAKADA E ET AL: "C-terminal LRRs of human Toll-like receptor 3 control receptor dimerization and signal transmission", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 15, 1 July 2007 (2007-07-01), pages 3633 - 3640, XP025320882, ISSN: 0161-5890, [retrieved on 20070530], DOI: 10.1016/J.MOLIMM.2007.04.021 *

Also Published As

Publication number Publication date
CA2824313A1 (fr) 2012-07-19
EP2663329A2 (fr) 2013-11-20
US20140065154A1 (en) 2014-03-06
WO2012095432A2 (fr) 2012-07-19
AU2012206614A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
EP3838921A3 (fr) Anticorps dirigés contre tau
MX2018010572A (es) Inmunoglobulinas heterodimericas.
WO2014145159A3 (fr) Anticorps à charge génétiquement modifiée ou compositions de protéines de ciblage à pénétration améliorée et méthodes d'utilisation
WO2012118903A3 (fr) Agents liants bispécifiques
WO2013012921A3 (fr) Aptamères d'acide nucléique
WO2011047146A3 (fr) Procédés de maturation d'affinité d'anticorps
EP2621499A4 (fr) Méthodes de traitement de maladies allergiques
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
WO2013063391A3 (fr) Animaux transgéniques et leurs procédés d'utilisation
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
WO2011142970A3 (fr) Aptamères d'acide nucléique her2
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
WO2012109238A3 (fr) Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
WO2013106273A3 (fr) Peptides et leurs méthodes d'utilisation
GB201109238D0 (en) Antibodies
HK1249016A1 (zh) 使用抗il-34抗體治療神經疾病的組合物和方法
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2013023059A3 (fr) Méthodes et compositions pour le traitement de maladies auto-immunes et inflammatoires
MX2014014443A (es) Agentes de ligacion a tlr3.
WO2012095432A3 (fr) Agents de liaison à tlr3
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
WO2013122544A3 (fr) Anticorps monoclonaux humains neutralisant il-1β

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12700056

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2824313

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012700056

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012206614

Country of ref document: AU

Date of ref document: 20120110

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13979370

Country of ref document: US